Sign in

    Joori Park

    Research Analyst at Leerink Partners

    Joori Park, Ph.D., is an Equity Research Analyst at Leerink Partners, specializing in biotechnology and rare disease sectors. Park covers biopharmaceutical companies such as Larimar Therapeutics (LRMR), Janux Therapeutics (JANX), Pyxis Oncology (PYXS), Xencor (XNCR), and Zai Lab Ltd (ZLAB), with a coverage record notable for recent initiations but currently reflecting a 0% success rate and an average return of -73.99%. Her analyst career began at Leerink Partners, where she has focused on healthcare equities since at least late 2024, as indicated by coverage lists, though prior experience at other firms is not documented. Park is listed with a Ph.D. credential, and is directly reachable via her Leerink Partners contact, though specific FINRA registration or securities licenses information is not publicly disclosed.

    Joori Park's questions to Ascendis Pharma (ASND) leadership

    Joori Park's questions to Ascendis Pharma (ASND) leadership • Q2 2025

    Question

    Joori Park from Leerink Partners, on for Joseph Schwartz, asked what portion of the target physician base the 1,500 Yorvipath prescribers represent, and for perspective on a competitor's CNP drug having a higher AUC.

    Answer

    Jay Donovan Wu, EVP & President - US Market, stated the target universe is 8,000-10,000 physicians, with 3,000 considered high-priority, and they have achieved over 80% reach within that priority group. President & CEO Jan Møller Mikkelsen addressed the competitor question by emphasizing that a sustained profile without high peak concentrations (Cmax) is critical to avoid hypotension, dismissing AUC as a key metric without full profile data and expressing confidence in their combination therapy approach.

    Ask Fintool Equity Research AI

    Joori Park's questions to Protagonist Therapeutics (PTGX) leadership

    Joori Park's questions to Protagonist Therapeutics (PTGX) leadership • Q4 2019

    Question

    Joori Park, on behalf of Joseph Schwartz from SVB Leerink LLC, asked for clarity on the timing of the PTG-300 TRANSCEND data release, the expected level of improvement of PN-943 over PTG-100, details on the upcoming Phase II trial design, and the strategy to ensure timely trial enrollment amidst competition.

    Answer

    President and CEO Dinesh Patel stated that full clinical efficacy data for PTG-300 would be shared in 2020 once conclusive findings are reached for each indication. He noted that PN-943 was roughly threefold more effective than PTG-100 in a Phase I study. The upcoming Phase II trial for PN-943 will be a comprehensive study with high and low doses and a placebo arm, with more details to be shared in Q2. Mr. Patel expressed confidence in meeting enrollment timelines due to the drug's attractive profile as a proven, oral, GI-restricted agent.

    Ask Fintool Equity Research AI